Characterization of a new monoclonal antibody F4 detecting cell surface epitope and P-glycoprotein in drug-resistant human tumor cell lines.
Using viable adriamycin resistant human ovarian carcinoma cells 2780AD and colchicine resistant human oral epidermoid carcinoma cells KB-24 as the immunogen in primary and subsequent i.p. immunizations, followed by i.v. boostings with crude plasma membranes of 2780AD, KB-24, Chinese hamster lung cells resistant to vincristine DC-3F/VCRd-5L, and resistant to daunorubicin DC-3F/DMXX, we have generated a new murine monoclonal antibody (McAb), designated F4, of IgG1 isotype. McAb F4 reacted strongly with a cell surface epitope of drug resistant cells and insignificantly with their drug sensitive counterparts. Cell surface localization of F4 epitope was determined by immunofluorescence and laser scanning confocal imaging system. Results obtained from immunoprecipitation and immunoblot analyses using F4 and mdr1 P-glycoprotein specific McAb JSB-1 demonstrated the reactivity of P-glycoprotein with F4. These results along with those obtained from competitive binding-inhibition, chemical modification, and enzyme hydrolysis, revealed that McAb F4 detects an extracellular epitope of P-glycoprotein, and is different from other major McAbs directed against P-glycoprotein, e.g. C219, MRK16, JSB-1, HYB-241 and C494. Deduced from the putative structure of mdr1 protein and its orientation in cell membrane, it is proposed that F4 epitope is localized in or near the 3rd, and/or 6th extracellular transmembrane loops of P-glycoprotein.
Chu
T M
TM
Department of Diagnostic Immunology Research and Biochemistry, Roswell Park Cancer Institute, New York State Department of Health, Buffalo 14263.
Kawinski
E
E
Lin
T H
TH
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000912:Antibodies, Neoplasm / Q000276:immunology*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D000954:Antigens, Surface / Q000276:immunology*; D001943:Breast Neoplasms / Q000276:immunology; D016466:CHO Cells / Q000187:drug effects / Q000276:immunology; D002352:Carrier Proteins / Q000276:immunology*; D006224:Cricetinae; D003630:Daunorubicin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006801:Humans; D007624:KB Cells / Q000187:drug effects / Q000276:immunology; D008562:Membrane Glycoproteins / Q000276:immunology*; D009363:Neoplasm Proteins / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000276:immunology; D017434:Protein Structure, Tertiary; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014750:Vincristine / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D002352:Carrier Proteins; D000939:Epitopes; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D014750:Vincristine; D004317:Doxorubicin; D003630:Daunorubicin